“`html
Granules India Ltd is a prominent Indian pharmaceutical company that has carved a niche in producing high-quality, affordable medicines. Founded in 1984, this organization thrives on a specialized focus on manufacturing Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages. Granules India caters to a wide array of healthcare needs, providing medications aimed at alleviating common health issues, including pain relief, diabetes management, and hypertension treatment. As a vital player in the pharmaceutical sector, the company’s commitment to quality and affordability resonates well with its clientele globally.
Currently, Granules India exports its products to over 75 countries, engaging in partnerships with renowned pharmaceutical companies around the globe. As of October 16, 2024, the Granules Share Price on the NSE stands at 604.85 INR. In this article, we will delve deeper into Granules India’s share price trends and targets for 2024, 2025, 2026, and beyond, providing insights into the company’s market standing, financial health, and competitive landscape.
Granules India Ltd: Market Overview
| Market Data | Value |
| Open Price: | ₹599.90 |
| High Price: | ₹599.90 |
| Low Price: | ₹599.90 |
| Previous Close: | ₹599.65 |
| Volume: | 43,481 |
| Value (Lacs): | ₹260.95 |
| VWAP: | ₹600.30 |
| UC Limit: | ₹659.60 |
| LC Limit: | ₹539.70 |
| P/E ratio: | 29.56 |
| Div yield: | 0.25% |
| 52-wk high: | ₹721.00 |
| 52-wk low: | ₹318.95 |
| Mkt cap: | ₹14.54KCr |
| Face Value: | ₹1 |
Granules India Ltd Competitors
In the competitive pharmaceutical landscape, Granules India Ltd faces numerous rivals. Below are five notable competitors, along with their respective market capitalizations as of the latest available data:
- Aurobindo Pharma Ltd
- Market Capitalization: ~$4.6 billion
- Aurobindo is recognized as a significant player in producing APIs, generic formulations, and nutraceuticals across various therapeutic areas.
- Sun Pharmaceutical Industries Ltd
- Market Capitalization: ~$33 billion
- Sun Pharma holds a leading position in India’s pharmaceutical sector, specializing in generic drugs, branded generics, and APIs.
- Cipla Ltd
- Market Capitalization: ~$12.8 billion
- Cipla is prominent in the areas of respiratory, antiretroviral, urology, and cardiovascular treatments, along with offering APIs and generic formulations.
- Dr. Reddy’s Laboratories Ltd
- Market Capitalization: ~$10.8 billion
- This company is a global pharmaceutical entity that provides a broad range of products, including APIs, generic medications, and over-the-counter solutions.
- Lupin Ltd
- Market Capitalization: ~$6.4 billion
- Lupin engages in the manufacturing of both branded and generic drugs, biosimilars, and APIs across diverse therapeutic segments.
Granules Share Price Chart
Granules Share Price Target for 2024 to 2030
| Year | Expected Share Price Target (INR) |
| 2024 | ₹750 |
| 2025 | ₹865 |
| 2026 | ₹990 |
| 2027 | ₹1130 |
| 2028 | ₹1295 |
| 2029 | ₹1480 |
| 2030 | ₹1692 |
Granules Share Price Target 2024
The expected target for Granules share price in 2024 is ₹750. Several pivotal factors could influence this growth trajectory:
- Demand for Generic Medicines: With Granules India’s focus on affordable generic drugs, the company could see an increase in revenues due to the rising demand for generics, particularly in key markets like the U.S. and Europe.
- Expansion of Product Portfolio: Granules India is keen on growth through diversification. Successful launches of new drugs can significantly contribute to earnings growth and enhance investor confidence, especially in high-demand therapeutic segments.
- Regulatory Approvals and Compliance: The ability to navigate regulatory environments, including securing approvals from institutions such as the U.S. FDA for new products, remains crucial. Regulatory advancements can lead to positive stock performance, while regulatory setbacks could dampen investor sentiment.
Granules Share Price Target 2025
The expected target for Granules share price in 2025 is ₹865. The anticipated growth factors are as follows:
- Global Market Expansion and Exports: Exploring new international markets will be key to Granules India’s profitability. Expansion into North America, Europe, and emerging markets can significantly boost revenues and positively influence the share price.
- Cost Management and Operational Efficiency: In a highly competitive market, cost management and production efficiency will determine profitability margins. Streamlining operations can lead to a stronger financial position and favorable stock performance.
- Strategic Partnerships and Acquisitions: Building partnerships and exploring acquisitions can enhance Granules’ product offerings and market presence. Successful collaborations can create new revenue streams and positively affect share price.
Granules Share Price Target 2030
The expected target for Granules share price in 2030 is ₹1692. Key drivers influencing this long-term growth may include:
- Long-Term Growth in Healthcare Demand: The demand for affordable healthcare solutions is projected to rise significantly, driven by aging populations and emerging markets. Granules India’s efficient production capabilities position it favorably for capitalizing on this trend.
- Innovation and R&D Investment: Continued investment in research and development will be critical for Granules India. Innovations in drug formulations, complex gener